Copyright Reports & Markets. All rights reserved.

Global Non-Benzodiazepines Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Non-Benzodiazepines by Type
    • 1.3.1 Overview: Global Non-Benzodiazepines Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Non-Benzodiazepines Consumption Value Market Share by Type in 2025
    • 1.3.3 Zolpidem
    • 1.3.4 Zopiclone
    • 1.3.5 Eszopiclone
    • 1.3.6 Zaleplon
  • 1.4 Classification of Non-Benzodiazepines by Dosage Form
    • 1.4.1 Overview: Global Non-Benzodiazepines Market Size by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Non-Benzodiazepines Consumption Value Market Share by Dosage Form in 2025
    • 1.4.3 Tablets
    • 1.4.4 Capsules
    • 1.4.5 Other
  • 1.5 Classification of Non-Benzodiazepines by Product Status
    • 1.5.1 Overview: Global Non-Benzodiazepines Market Size by Product Status: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Non-Benzodiazepines Consumption Value Market Share by Product Status in 2025
    • 1.5.3 Originator Drugs
    • 1.5.4 Generic Drugs
  • 1.6 Global Non-Benzodiazepines Market by Application
    • 1.6.1 Overview: Global Non-Benzodiazepines Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Clinic
    • 1.6.4 Others
  • 1.7 Global Non-Benzodiazepines Market Size & Forecast
  • 1.8 Global Non-Benzodiazepines Market Size and Forecast by Region
    • 1.8.1 Global Non-Benzodiazepines Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Non-Benzodiazepines Market Size by Region, (2021-2032)
    • 1.8.3 North America Non-Benzodiazepines Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Non-Benzodiazepines Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Non-Benzodiazepines Market Size and Prospect (2021-2032)
    • 1.8.6 South America Non-Benzodiazepines Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Non-Benzodiazepines Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Cosette Pharmaceuticals
    • 2.1.1 Cosette Pharmaceuticals Details
    • 2.1.2 Cosette Pharmaceuticals Major Business
    • 2.1.3 Cosette Pharmaceuticals Non-Benzodiazepines Product and Solutions
    • 2.1.4 Cosette Pharmaceuticals Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Cosette Pharmaceuticals Recent Developments and Future Plans
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Non-Benzodiazepines Product and Solutions
    • 2.2.4 Sanofi Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments and Future Plans
  • 2.3 Sumitomo Pharma
    • 2.3.1 Sumitomo Pharma Details
    • 2.3.2 Sumitomo Pharma Major Business
    • 2.3.3 Sumitomo Pharma Non-Benzodiazepines Product and Solutions
    • 2.3.4 Sumitomo Pharma Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sumitomo Pharma Recent Developments and Future Plans
  • 2.4 Teva Pharmaceutical Industries
    • 2.4.1 Teva Pharmaceutical Industries Details
    • 2.4.2 Teva Pharmaceutical Industries Major Business
    • 2.4.3 Teva Pharmaceutical Industries Non-Benzodiazepines Product and Solutions
    • 2.4.4 Teva Pharmaceutical Industries Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
  • 2.5 Viatris
    • 2.5.1 Viatris Details
    • 2.5.2 Viatris Major Business
    • 2.5.3 Viatris Non-Benzodiazepines Product and Solutions
    • 2.5.4 Viatris Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Viatris Recent Developments and Future Plans
  • 2.6 Sandoz
    • 2.6.1 Sandoz Details
    • 2.6.2 Sandoz Major Business
    • 2.6.3 Sandoz Non-Benzodiazepines Product and Solutions
    • 2.6.4 Sandoz Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sandoz Recent Developments and Future Plans
  • 2.7 Sun Pharmaceutical Industries
    • 2.7.1 Sun Pharmaceutical Industries Details
    • 2.7.2 Sun Pharmaceutical Industries Major Business
    • 2.7.3 Sun Pharmaceutical Industries Non-Benzodiazepines Product and Solutions
    • 2.7.4 Sun Pharmaceutical Industries Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
  • 2.8 Dr. Reddy's Laboratories
    • 2.8.1 Dr. Reddy's Laboratories Details
    • 2.8.2 Dr. Reddy's Laboratories Major Business
    • 2.8.3 Dr. Reddy's Laboratories Non-Benzodiazepines Product and Solutions
    • 2.8.4 Dr. Reddy's Laboratories Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
  • 2.9 Aurobindo Pharma
    • 2.9.1 Aurobindo Pharma Details
    • 2.9.2 Aurobindo Pharma Major Business
    • 2.9.3 Aurobindo Pharma Non-Benzodiazepines Product and Solutions
    • 2.9.4 Aurobindo Pharma Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Aurobindo Pharma Recent Developments and Future Plans
  • 2.10 Lupin
    • 2.10.1 Lupin Details
    • 2.10.2 Lupin Major Business
    • 2.10.3 Lupin Non-Benzodiazepines Product and Solutions
    • 2.10.4 Lupin Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Lupin Recent Developments and Future Plans
  • 2.11 Torrent Pharmaceuticals
    • 2.11.1 Torrent Pharmaceuticals Details
    • 2.11.2 Torrent Pharmaceuticals Major Business
    • 2.11.3 Torrent Pharmaceuticals Non-Benzodiazepines Product and Solutions
    • 2.11.4 Torrent Pharmaceuticals Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Torrent Pharmaceuticals Recent Developments and Future Plans
  • 2.12 Jiangsu Nhwa Pharmaceutical
    • 2.12.1 Jiangsu Nhwa Pharmaceutical Details
    • 2.12.2 Jiangsu Nhwa Pharmaceutical Major Business
    • 2.12.3 Jiangsu Nhwa Pharmaceutical Non-Benzodiazepines Product and Solutions
    • 2.12.4 Jiangsu Nhwa Pharmaceutical Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Jiangsu Nhwa Pharmaceutical Recent Developments and Future Plans
  • 2.13 Shanghai Pharmaceuticals
    • 2.13.1 Shanghai Pharmaceuticals Details
    • 2.13.2 Shanghai Pharmaceuticals Major Business
    • 2.13.3 Shanghai Pharmaceuticals Non-Benzodiazepines Product and Solutions
    • 2.13.4 Shanghai Pharmaceuticals Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Shanghai Pharmaceuticals Recent Developments and Future Plans
  • 2.14 Qilu Pharmaceutical
    • 2.14.1 Qilu Pharmaceutical Details
    • 2.14.2 Qilu Pharmaceutical Major Business
    • 2.14.3 Qilu Pharmaceutical Non-Benzodiazepines Product and Solutions
    • 2.14.4 Qilu Pharmaceutical Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Qilu Pharmaceutical Recent Developments and Future Plans
  • 2.15 Chengdu Kanghong Pharmaceutical Group
    • 2.15.1 Chengdu Kanghong Pharmaceutical Group Details
    • 2.15.2 Chengdu Kanghong Pharmaceutical Group Major Business
    • 2.15.3 Chengdu Kanghong Pharmaceutical Group Non-Benzodiazepines Product and Solutions
    • 2.15.4 Chengdu Kanghong Pharmaceutical Group Non-Benzodiazepines Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Chengdu Kanghong Pharmaceutical Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Non-Benzodiazepines Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Non-Benzodiazepines by Company Revenue
    • 3.2.2 Top 3 Non-Benzodiazepines Players Market Share in 2025
    • 3.2.3 Top 6 Non-Benzodiazepines Players Market Share in 2025
  • 3.3 Non-Benzodiazepines Market: Overall Company Footprint Analysis
    • 3.3.1 Non-Benzodiazepines Market: Region Footprint
    • 3.3.2 Non-Benzodiazepines Market: Company Product Type Footprint
    • 3.3.3 Non-Benzodiazepines Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Non-Benzodiazepines Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Non-Benzodiazepines Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Non-Benzodiazepines Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Non-Benzodiazepines Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Non-Benzodiazepines Consumption Value by Type (2021-2032)
  • 6.2 North America Non-Benzodiazepines Market Size by Application (2021-2032)
  • 6.3 North America Non-Benzodiazepines Market Size by Country
    • 6.3.1 North America Non-Benzodiazepines Consumption Value by Country (2021-2032)
    • 6.3.2 United States Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Non-Benzodiazepines Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Non-Benzodiazepines Consumption Value by Type (2021-2032)
  • 7.2 Europe Non-Benzodiazepines Consumption Value by Application (2021-2032)
  • 7.3 Europe Non-Benzodiazepines Market Size by Country
    • 7.3.1 Europe Non-Benzodiazepines Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 7.3.3 France Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Non-Benzodiazepines Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Non-Benzodiazepines Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Non-Benzodiazepines Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Non-Benzodiazepines Market Size by Region
    • 8.3.1 Asia-Pacific Non-Benzodiazepines Consumption Value by Region (2021-2032)
    • 8.3.2 China Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 8.3.5 India Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Non-Benzodiazepines Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Non-Benzodiazepines Consumption Value by Type (2021-2032)
  • 9.2 South America Non-Benzodiazepines Consumption Value by Application (2021-2032)
  • 9.3 South America Non-Benzodiazepines Market Size by Country
    • 9.3.1 South America Non-Benzodiazepines Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Non-Benzodiazepines Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Non-Benzodiazepines Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Non-Benzodiazepines Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Non-Benzodiazepines Market Size by Country
    • 10.3.1 Middle East & Africa Non-Benzodiazepines Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Non-Benzodiazepines Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Non-Benzodiazepines Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Non-Benzodiazepines Market Drivers
  • 11.2 Non-Benzodiazepines Market Restraints
  • 11.3 Non-Benzodiazepines Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Non-Benzodiazepines Industry Chain
  • 12.2 Non-Benzodiazepines Upstream Analysis
  • 12.3 Non-Benzodiazepines Midstream Analysis
  • 12.4 Non-Benzodiazepines Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Non-Benzodiazepines market size was valued at US$ 1216 million in 2025 and is forecast to a readjusted size of US$ 1479 million by 2032 with a CAGR of 2.8% during review period.
    Non-benzodiazepines are prescription sedative-hypnotics primarily represented by zolpidem, zopiclone, eszopiclone, and zaleplon. Although chemically distinct from conventional benzodiazepines, they mainly enhance GABAergic inhibitory neurotransmission through positive allosteric modulation of benzodiazepine recognition sites on GABAA receptors and are used to treat sleep-onset difficulty, frequent nocturnal awakening, early awakening, and sleep-maintenance insomnia. Major dosage forms include immediate-release tablets, extended-release tablets, capsules, sublingual tablets, orally disintegrating tablets, and oral sprays. Upstream inputs mainly include zolpidem tartrate, zopiclone, eszopiclone, and zaleplon active pharmaceutical ingredients, together with fillers, disintegrants, coating materials, extended-release excipients, capsule shells, spray-pump components, and pharmaceutical packaging materials. Downstream customers mainly include general hospitals, psychiatric hospitals, sleep clinics, primary care institutions, retail pharmacies, regulated online prescription platforms, and pharmaceutical distributors. Competition is intense in standard generic tablets, while extended-release tablets, sublingual products, oral sprays, and established branded products retain higher added value, with an overall gross margin generally ranging from approximately 45% to 68%.
    From the current market perspective, non-benzodiazepines form a mature market dominated by zolpidem, with zopiclone and eszopiclone representing important secondary segments and zaleplon accounting for a relatively small share. All major active ingredients are exposed to generic competition, and standard tablets are supplied by numerous manufacturers. Zolpidem and eszopiclone are more prominent in the United States, while zopiclone is widely used in Europe, Canada, and parts of Asia.
    Looking ahead, market innovation will focus mainly on dosage-form optimization, lower-dose treatment, precision dosing, and medication safety. Standard tablets will continue to account for most volume, while extended-release tablets, sublingual tablets, orally disintegrating tablets, oral sprays, and low-dose products for middle-of-the-night awakening offer greater differentiation. Manufacturers will place greater emphasis on next-day impairment, complex sleep behaviors, falls in older patients, and dependence management.
    Key market drivers include faster-paced lifestyles, psychological stress, population aging, increasing diagnosis of insomnia, and greater awareness of sleep health. These medicines have rapid onset, broad physician familiarity, and widespread generic availability. Their treatment costs are generally lower than those of newer-mechanism medicines such as orexin receptor antagonists, supporting continued use in hospitals, primary care institutions, and retail prescription markets.
    The main constraints include next-day somnolence, cognitive and motor impairment, falls, tolerance, dependence, withdrawal, and complex sleep behaviors such as sleepwalking and sleep driving. Many jurisdictions impose prescription-duration limits, dose restrictions, and controlled-drug requirements. Cognitive behavioral therapy, digital sleep interventions, orexin receptor antagonists, and other new-mechanism insomnia treatments will also divert some chronic-insomnia patients.
    This report is a detailed and comprehensive analysis for global Non-Benzodiazepines market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Non-Benzodiazepines market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Non-Benzodiazepines market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Non-Benzodiazepines market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Non-Benzodiazepines market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Non-Benzodiazepines
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Non-Benzodiazepines market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cosette Pharmaceuticals, Sanofi, Sumitomo Pharma, Teva Pharmaceutical Industries, Viatris, Sandoz, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Non-Benzodiazepines market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Zolpidem
    Zopiclone
    Eszopiclone
    Zaleplon
    Market segment by Dosage Form
    Tablets
    Capsules
    Other
    Market segment by Product Status
    Originator Drugs
    Generic Drugs
    Market segment by Application
    Hospital
    Clinic
    Others
    Market segment by players, this report covers
    Cosette Pharmaceuticals
    Sanofi
    Sumitomo Pharma
    Teva Pharmaceutical Industries
    Viatris
    Sandoz
    Sun Pharmaceutical Industries
    Dr. Reddy's Laboratories
    Aurobindo Pharma
    Lupin
    Torrent Pharmaceuticals
    Jiangsu Nhwa Pharmaceutical
    Shanghai Pharmaceuticals
    Qilu Pharmaceutical
    Chengdu Kanghong Pharmaceutical Group
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Non-Benzodiazepines product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Non-Benzodiazepines, with revenue, gross margin, and global market share of Non-Benzodiazepines from 2021 to 2026.
    Chapter 3, the Non-Benzodiazepines competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Non-Benzodiazepines market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Benzodiazepines.
    Chapter 13, to describe Non-Benzodiazepines research findings and conclusion.

    Buy now